Andrea Harkin

8PUBLICATIONS
105CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersCancer genetics
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Jan 09, 2026
Three Versus 6 Months of Adjuvant Oxaliplatin-Fluoropyrimidine Chemotherapy for Colorectal Cancer: Final Results of SCOT-An International, Randomized, Phase III, Noninferiority Trial.

Timothy Iveson, Mark P Saunders, Caroline Kelly

|Mar 28, 2024
Oxaliplatin-Based Adjuvant Chemotherapy in Older Patients With Stage III Colon Cancer: An ACCENT/IDEA Pooled Analysis of 12 Trials.

Claire Gallois, Qian Shi, Levi D Pederson

|Mar 14, 2024
Prognostic and Predictive Value of Immunoscore in Stage III Colorectal Cancer: Pooled Analysis of Cases From the SCOT and IDEA-HORG Studies.

Enric Domingo, Caroline Kelly, Jennifer Hay

|Nov 09, 2021
Early-Onset Colorectal Adenocarcinoma in the IDEA Database: Treatment Adherence, Toxicities, and Outcomes With 3 and 6 Months of Adjuvant Fluoropyrimidine and Oxaliplatin.

Elisa Fontana, Jeff Meyers, Alberto Sobrero

|Jun 23, 2021
Patients' Preferences for 3 Months vs 6 Months of Adjuvant Chemotherapy for Colon Cancer.

Prunella Blinman, Andrew Martin, Michael Jefford

|Jan 13, 2021
Duration of Adjuvant Doublet Chemotherapy (3 or 6 months) in Patients With High-Risk Stage II Colorectal Cancer.

Timothy J Iveson, Alberto F Sobrero, Takayuki Yoshino

Pageof 2

Frequent Collaborators

7 joint publications

Timothy J Iveson

3 joint publications

Niels Henrik Hollander

3 joint publications

Qian Shi

3 joint publications

Ioannis Boukovinas